CTOs on the Move

Daiichi Sankyo

www.dsi.com

 
Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey. Our team of more than 1,400 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. We currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioid-induced constipation and metastatic melanoma. With over 100 years of scientific expertise and a presence in more ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion
  • www.dsi.com
  • 211 Mt. Airy Road
    Basking Ridge, NJ USA 07920
  • Phone: 908.992.6400

Executives

Name Title Contact Details
Paulette Gangemi
Senior Director, Employee Relations and Employment Practices (HR) Profile

Similar Companies

South Pacific Bio Medical

South Pacific Bio Medical is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OMICS Group Inc

OMICS Group Inc is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayhill Therapeutics

Bayhill Therapeutics is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

US Bio Solutions

US Bio Solutions is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greffex

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex`s team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.